Drug intelligence / Profile preview

favipiravir + tocilizumab

Development stage: Unknown
Lead developer: FUJIFILM Toyama Chemical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of favipiravir, an antiviral medication that inhibits viral RNA polymerase, while tocilizumab is a monoclonal antibody that blocks the interleukin-6 receptor, reducing inflammation. Together, they target both the viral replication and the inflammatory response in COVID-19 patients. The combination has been studied for the treatment of COVID-19, particularly in patients with elevated IL-6 levels. Clinical trials have shown that the combination can effectively improve pulmonary inflammation and prevent disease deterioration in COVID-19 patients.

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)IL-6R (Interleukin-6 receptor subunit alpha)

Beyond the preview

Go deeper on favipiravir + tocilizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on favipiravir + tocilizumab.

Explore the full profile